The therapeutic effects of minocycline in methamphetamine related-neuropsychological disorders

Evaluation of the effect of minocycline on methamphetamine related-neuropsychological disorders

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016102630510N1

Enrollment

Registered

2017-01-06

Start date

2016-12-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Substance abuse. Mental and behavioural disorders due to psychoactive substance use

Interventions

Intervention group: The patients will receive daily oral 200 mg of minocycline for two months..

Treatment - Drugs

Intervention group: The patients will receive daily oral 200 mg of minocycline for two months.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Inclusion criteria: Methamphetamine users that have methamphetamine related-neuropsychological disorders and are seeking for a treatment; age more than 18; the duration of methamphetamine use is at least 1 year. Exclusion criteria: Side effects related to minocycline, relapse to methamphetamine use.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Neurocognitive impairment. Timepoint: time 0, 2 weeks, 1 month and 2 months after start of intervention and 2 months after finishing intevention. Method of measurement: Neuropsychological tools.	—

Secondary

Measure	Time frame
Side effects, such as headache, nausea and. Timepoint: during the intervention and 2 months after that. Method of measurement: questionnaire or observation.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammad Bagher Saberi zafarghandi

Iran University of medical science

saberiza4@yahoo.com+98 21 6655 1658

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026